Romuald Corbau
Hoofd Techniek/Wetenschap/O&O bij ADVERUM BIOTECHNOLOGIES, INC.
Profiel
Romuald Corbau is currently the Chief Scientific Officer at Adverum Biotechnologies, Inc. He previously held the same position at Freeline Therapeutics Holdings Plc from 2020 to 2021.
Additionally, he served as the Chief Scientific Officer at GenEdit, Inc. Dr. Corbau is a graduate of Université des Sciences et Technologies de Lille.
Actieve functies van Romuald Corbau
| Bedrijven | Functie | Begin |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Hoofd Techniek/Wetenschap/O&O | 29-01-2024 |
Eerdere bekende functies van Romuald Corbau
| Bedrijven | Functie | Einde |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Hoofd Techniek/Wetenschap/O&O | 20-08-2021 |
GenEdit, Inc.
 GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Romuald Corbau
| Université des Sciences et Technologies de Lille | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
GenEdit, Inc.
GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Health Technology |
